Iptacopan in Patients With ANCA Associated Vasculitis
Iptacopan in Patients With ANCA Associated Vasculitis
Active, not recruiting · NCT06388941 · Registry updated 2026-08-20Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Iptacopan in Patients With ANCA Associated Vasculitis | Cerebral Small Vessel Diseases, Skin and Connective Tissue Diseases, anti-neutrophil cytoplasmic antibody-associated vasculitis, autoimmune disease, brain disorder, cardiovascular disorder, central nervous system disorder, cerebrovascular disorder, granulomatosis with polyangiitis, immune system disorder, interstitial lung disease, lung disorder, microscopic polyangiitis, necrotizing vasculitis, nervous system disorder, respiratory system disorder, skin disorder, skin vascular disease, vascular disorder, vasculitis | Active, not recruiting | Phase 2 | 2026-08-20 | NCT06388941 |
1 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Novartis Pharmaceuticals | 432 |
2 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Arizona Arthritis and Rheumatology Research PLLC | Mesa | United States | 2 |
| Mayo Clinic Rochester | Rochester | United States | 133 |